Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2010
04/01/2010US20100080793 DcR3 polypeptide, A TNFR homolog
04/01/2010US20100080791 Composition and Method For Treating Tissue Defects
04/01/2010US20100080789 Therapeutic ribonucleases
04/01/2010US20100080788 Alginate and alginate lyase compositions and methods of use
04/01/2010US20100080787 Cosmetic or dermopharmaceutical composition comprising an enzyme which is insoluble in an aqueous medium as well as its uses
04/01/2010US20100080786 Phenyl or Pyridinyl Substituted Indazoles Derivatives
04/01/2010US20100080785 Dried formulations
04/01/2010US20100080778 Stem cell expansion enhancing factor and method of use
04/01/2010US20100080776 Method of enhancing an immune response
04/01/2010US20100080775 Recombinant adenoviruses encoding the specific iodine transporter (nis)
04/01/2010US20100080773 Orally Bioavailable Lipid-Based Constructs
04/01/2010US20100080772 Hepatitis C Virus Inhibitors
04/01/2010US20100080771 Hepatitis C Virus Inhibitors
04/01/2010US20100080770 Hepatitis C Virus Inhibitors
04/01/2010US20100080769 Treatment of Chronic Lymphocytic Leukemia using Anti-CD20 Antibodies
04/01/2010US20100080764 Skin Treatment Systems
04/01/2010US20100080756 Methods for protecting and regenerating bone marrow using cxcr3 agonists and antagonists
04/01/2010DE102008049767A1 N-geschützte Guanidin-substituierte Furane, Thiophene und Pyrrole als Cystein-Protease-Inhibitoren N-protected guanidine-substituted furans, thiophenes and pyrroles as cysteine ​​protease inhibitors
04/01/2010CA2738605A1 Composition and method for treatment of preterm labor
04/01/2010CA2738549A1 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
04/01/2010CA2738477A1 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis
04/01/2010CA2738280A1 Peptide compound and method for producing the same
04/01/2010CA2738274A1 Complex consisting of polysaccharide and an hpb
04/01/2010CA2738209A1 Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation
04/01/2010CA2737953A1 Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
04/01/2010CA2736729A1 Amyloid beta-peptides and methods of use thereof
04/01/2010CA2736529A1 Methods of modulating protein homeostasis, metabolic syndrome, heavy metal intoxication and nrf2 transcription factors
03/2010
03/31/2010EP2169067A1 Recombinant production of serum albumin
03/31/2010EP2168983A1 New octapeptide compounds and their therapeutic use
03/31/2010EP2168982A1 GLP-1 analog fusion protein formulations
03/31/2010EP2168981A2 A Fibrin/Fibrinogen-binding conjugate
03/31/2010EP2168978A2 Amino acid and nucleic acid sequences and vaccine to control ectoparasite infestations in fish
03/31/2010EP2168976A1 Antimicrobial peptides
03/31/2010EP2168975A2 Stable protein storage and stable nucleic acid storage in recoverable form
03/31/2010EP2168954A1 Cysteine proteases inhibitors
03/31/2010EP2168603A1 Therapeutic regimen for treating cancer
03/31/2010EP2168602A1 Site-specific pegylated linear salmon calcitonin derivatives
03/31/2010EP2168598A1 Method of Treatment Using Ligand-Immunogen Conjugates
03/31/2010EP2168596A2 Immunisation against chlamydia trachomatis
03/31/2010EP2168592A1 Antimicrobial peptides
03/31/2010EP2168591A1 Antimicrobial peptides
03/31/2010EP2168590A1 Antimicrobial peptides
03/31/2010EP2168581A2 Stable polymorph of N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
03/31/2010EP2167684A2 Targeting of sall4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (mds)
03/31/2010EP2167657A2 Use of a chromatography substrate for reducing the amount of adamts13 in a solution derived from plasma
03/31/2010EP2167537A2 Compiled methods for analysing and sorting samples
03/31/2010EP2167536A1 Mhc multimers, methods for their generation, labeling and use
03/31/2010EP2167535A2 Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
03/31/2010EP2167534A2 Bioactive peptides and method of using same
03/31/2010EP2167527A2 Lantibiotic-based compounds having antimicrobial activity
03/31/2010EP2167132A1 Resuscitation fluid
03/31/2010EP2167129A2 Compounds and methods for the treatment of renal disease
03/31/2010EP2167118A1 Transmembrane prostatic acid phosphatase
03/31/2010EP2167117A1 Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
03/31/2010EP2167116A2 Peptides with high affinity for the prolactin receptor
03/31/2010EP2167115A2 Treatment for alzheimer's disease
03/31/2010EP2167114A2 Fibrin gel for controlled release of pdgf and uses thereof
03/31/2010EP2167113A2 Neuroplastin derived peptides
03/31/2010EP2167112A2 Cyclic peptide melanocortin receptor ligands
03/31/2010EP2167111A2 Polypeptides and methods of use
03/31/2010EP2167089A1 Therapeutic compositions and the use thereof
03/31/2010EP2167040A1 Intranasal carbetocin formulations and methods for the treatment of autism
03/31/2010EP2166876A1 Iron fortification nutritional blend
03/31/2010EP2166845A2 Alpha connexin c-terminal (act) peptides for treating age-related macular degeneration
03/31/2010EP1333823B1 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
03/31/2010EP1194168B1 Methods and products for manipulating uncoupling protein expression
03/31/2010EP1107989B1 Expression and export of angiostatin and endostatin as immunofusins
03/31/2010EP1104290B1 Microemulsions as solid dosage forms for oral administration
03/31/2010CN101688327A Serpine1 polymorphisms are predictive of response to activated protein c administration and risk of death
03/31/2010CN101688210A 促红细胞生成素融合蛋白 Erythropoietin fusion protein
03/31/2010CN101688205A Anti-tumor drug, medicament, composition, and use thereof
03/31/2010CN101688193A modified phosphatases
03/31/2010CN101688179A Recombinant protein production in avian ebx r cells
03/31/2010CN101687933A Immunoglobulin fusion proteins
03/31/2010CN101687918A Methods and compositions for the treatment of proliferative diseases
03/31/2010CN101687909A Composition for preventing or treating lung disease
03/31/2010CN101687908A Antigen determinant of rheumatoid arthritis-specific autoantibody and use thereof
03/31/2010CN101687856A Co-crystals and pharmaceutical compositions comprising the same
03/31/2010CN101687046A Pharmaceutical liquid composition of botulinum toxin with improved stability
03/31/2010CN101687019A Medicaments and methods to treat autoimmune disease and cancer
03/31/2010CN101687018A Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in solid form
03/31/2010CN101687017A Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments
03/31/2010CN101687016A Activin-actriia antagonists and uses for promoting bone growth in cancer patients
03/31/2010CN101687015A Activin-actrii antagonists and uses for increasing red blood cell levels
03/31/2010CN101687014A compositions and methods for treating pathologic angiogenesis and vascular permeability
03/31/2010CN101687013A Use of cyclosporines in the treatment of patients with intraocular lenses
03/31/2010CN101687012A New cyclic peptide compounds
03/31/2010CN101687011A New treatment for chemical substance addiction
03/31/2010CN101687010A Romidepsin preparation
03/31/2010CN101687009A Methods of treatment of skin ulcers
03/31/2010CN101687008A Therapeutic agent and detection reagent for arteriosclerotic disease which targets for thallusin
03/31/2010CN101687007A Composition for prevention and/or treatment of peptic ulcer
03/31/2010CN101687006A reconstituted surfactants having improved properties
03/31/2010CN101687005A Methods for treating cancer using agents that inhibit wnt16 signaling
03/31/2010CN101686985A Cytotoxic t cell activator comprising ep4 agonist
03/31/2010CN101686975A Antitumour combinations containing a vegf inhibiting agent and irinotecan
03/31/2010CN101686971A Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies
03/31/2010CN101686960A Methods and compositions for contributing to the treatment of cancers
03/31/2010CN101686940A Method of delivering a protein into a cell
03/31/2010CN101684499A Compositions and methods for detection and treatment of proliferative abnormalities associated with overexpression of human transketolase like-1 gene
1 ... 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 ... 3163